Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 8/20 | 0.48 |
| ▸ | BCHE | P06276 | 8/20 | 0.45 |
| ▸ | CYBB | P04839 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14992015 | 0.89 | NOX4 (0.51) | NOX4BCHECYBBKDM4E | |
| SCHEMBL2216058 | 0.87 | NOX4 (0.45) | NOX4CYBBCYP2C9CYP2C19ABCB1 | |
| SCHEMBL2219796 | 0.87 | NOX4 (0.46) | NOX4BCHECYBBLMNAMEN1 | |
| SCHEMBL2217875 | 0.84 | NOX4 (0.51) | NOX4CYBBCYP2C9CYP2C19 | |
| SCHEMBL2216504 | 0.81 | NOX4 (0.57) | NOX4CYBBCYP2C9CYP2C19 | |
| SCHEMBL2219755 | 0.79 | NOX4 (0.54) | NOX4CYBB | |
| SCHEMBL2216036 | 0.76 | NOX4 (0.53) | NOX4CYBBCYP2C9CYP2C19KDM4E | |
| SCHEMBL2216293 | 0.74 | NOX4 (0.54) | NOX4BCHECYBBCYP2C9CYP2C19 | |
| SCHEMBL2219120 | 0.73 | NOX4 (0.46) | NOX4CYBBCYP2C9CYP2C19MEN1 | |
| SCHEMBL15163464 | 0.72 | NOX4 (0.45) | NOX4CYP2C9CYP2C19KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | disclosed |
| EP-2349261-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20130143879-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-06-06 | — | — | US | disclosed |
| US-8455485-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-06-04 | — | — | US | disclosed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143879-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885BCHE 1658/4885CYBB 3/4885 |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885BCHE 1658/4885CYBB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.